Cocrystal Pharma, Inc.

COCP • Biotechnology

$0.94

▼ -0.00 (-0.39%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$13.00M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.24Liquidez saludable · 3.68Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.94

Change-0.39%

Shares Out13.79M

Market Cap$13.00M

Enterprise Value$12.17M

52W Range0.76 - 2.67

Beta1.43

P/E-1.31

P/S57.78

P/B12.45

P/FCF-1.59

EV/Sales54.10

Price$0.94

Change-0.39%

Shares Out13.79M

Market Cap$13.00M

Enterprise Value$12.17M

52W Range0.76 - 2.67

Beta1.43

P/E-1.31

P/S57.78

P/B12.45

P/FCF-1.59

EV/Sales54.10

EV/EBITDA-1.26

EV/FCF-1.49

Earnings Yield-76.44%

FCF Yield-62.71%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.24

Current Ratio3.68

Quick Ratio3.68

Volume35.92K

Avg Volume85.21K

EPS Surprise-0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

89/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.24Liquidez saludable · 3.68Rentabilidad débil

Analyst view

Analyst sentiment and price target

COCP

Analyst sentiment

Based on 1 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 2/22/2012

Industria: Biotechnology

P/B i: 12.45

Deuda / Patrimonio i: 0.24

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.24

Ratio corriente: 3.68

Ratio rápido: 3.68

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

FROST PHILLIP MD ET AL

Transacción: 08/05/2026

COMPRA

Cambio

+10,000

Precio

$0.98

Presentación

08/06/2026

Tipo

COMPRA

FROST PHILLIP MD ET AL

Transacción: 08/03/2026

COMPRA

Cambio

+75,000

Precio

$0.94

Presentación

08/05/2026

Tipo

COMPRA

SAPIRSTEIN JAMES

Transacción: 06/03/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/03/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
FROST PHILLIP MD ET AL	COMPRA	+10,000	$0.98	08/05/2026	08/06/2026
FROST PHILLIP MD ET AL	COMPRA	+75,000	$0.94	08/03/2026	08/05/2026
SAPIRSTEIN JAMES	OTRO	0	Not reported	06/03/2026	06/03/2026
FROST PHILLIP MD ET AL	COMPRA	+20,000	$1.00	02/24/2026	02/25/2026
FROST PHILLIP MD ET AL	COMPRA	+50,000	$0.95	02/06/2026	02/09/2026
Rubin Steven D	COMPRA	+16,410	$1.10	01/09/2026	01/13/2026
Japour Anthony J	COMPRA	+16,410	$1.10	01/09/2026	01/13/2026
FROST PHILLIP MD ET AL	COMPRA	+24,615	$1.10	01/09/2026	01/13/2026
Martin James Joseph	COMPRA	+49,229	$1.10	01/09/2026	01/13/2026
Hassan Fred	COMPRA	+16,410	$1.10	01/09/2026	01/13/2026
Lee Sam	COMPRA	+49,229	$1.10	01/09/2026	01/13/2026
PFENNIGER RICHARD C JR	COMPRA	+16,410	$1.10	01/09/2026	01/13/2026
Kornberg Roger D.	COMPRA	+24,615	$1.10	01/09/2026	01/13/2026
FROST PHILLIP MD ET AL	COMPRA	+50,000	$0.95	12/31/2025	01/02/2026
FROST PHILLIP MD ET AL	COMPRA	+20,000	$0.97	12/30/2025	12/31/2025
FROST PHILLIP MD ET AL	COMPRA	+40,000	$0.97	12/26/2025	12/29/2025
FROST PHILLIP MD ET AL	COMPRA	+25,000	$0.97	12/24/2025	12/29/2025
FROST PHILLIP MD ET AL	COMPRA	+1,500	$1.00	11/26/2025	11/28/2025
FROST PHILLIP MD ET AL	COMPRA	+20,000	$0.94	11/25/2025	11/25/2025
Martin James Joseph	COMPRA	+7,196	$1.24	10/28/2025	10/30/2025

Sobre la compañía

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

Fuente - Link

Competidores

BOLT BRTX CING DWTX EVGN IMNN IMRN MRKR SNSE TRAW

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash.

GlobeNewsWire

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.

GlobeNewsWire

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus program toward Phase 1b topline data later this year.

GlobeNewsWire

Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA)

Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation. Institutional and Insider Ownership 35.0% of Zevra

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-21	-0.15	-0.16	-0.01
2026-05-15	-0.15	-0.17	-0.02
2025-11-14	-0.22	-0.19	0.03
2025-08-14	-0.3	-0.2	0.1
2025-05-15	-0.52	-0.23	0.29
2025-03-31	-0.55	-0.32	0.23
2024-11-13	-0.57	-0.49	0.08
2024-08-14	-0.51	-0.53	-0.02
2024-05-13	-0.54	-0.39	0.15
2024-03-28	-0.57	-0.44	0.13
2023-11-13	-0.47	-0.41	0.06
2023-08-14	-0.53	-0.5	0.03